RxDoctor Payments Data

Sridhar Ramachandran, MD

Internal Medicine · van Nuys, CANPI 1205937497

Payments from drug & device makers

$714in general payments, 2019–2025

Across 29 payments — averaging $24.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$160
  • AbbVie$120
  • Philips North America LLC$89
  • Lilly USA, LLC$53
  • Pfizer$44
  • Dexcom, Inc.$39
  • plus $210 from 8 others

What the payments were for

  • Food & beverage$714100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK5$160
AbbVie(2 entities)6$120
Philips North America LLC4$89
Lilly USA, LLC2$53
Pfizer2$44
Dexcom, Inc.1$39
Amgen1$34
Boehringer Ingelheim1$33
Sanofi-aventis U.S. LLC1$29
Merck2$25
AstraZeneca1$24
Aegerion Pharmaceuticals, Inc.1$23
Amarin Pharma, Inc.1$23
Astellas Pharma US Inc1$20

How this compares

$714 in reported general payments places this provider in the 70th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$100,531
Medicare patients
141
Services billed
961

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban42$27,840
JanuviaSitagliptin Phosphate13$14,174
LinzessLinaclotide17$11,529
SynthroidLevothyroxine Sodium19$2,615
Rosuvastatin Calcium97$1,476
Pregabalin12$1,431
Gabapentin73$971
Losartan Potassium147$951
Amlodipine Besylate195$938
Pantoprazole Sodium97$913
Celecoxib13$908
Atorvastatin Calcium131$843
Levothyroxine Sodium90$745
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen38$742
Metoprolol Succinate47$534

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$44$27,84042 claims
MerckJanuvia$25$14,17413 claims
AbbVieLinzess, Synthroid$120$14,14536 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 13,581 internal medicine providers in California.

Other internal medicine in van Nuys

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →